

EMMESSAR BIOTECH & NUTRITION LIMITED					
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31/03/2012					
Particulars	Rs in Lakhs				
	Current Qtr Ended 31.03.2012 Unaudited	Previous Qtr ended 31.12.2011 Unaudited	Corresponding 3 mths ended 31.03.2011 Unaudited	12 months Period Ended 31.03.2012 Unaudited	Year Ended 31.03.2011 Audited
01) Sales/Income from Operations (Gross)	50.61	14.42	15.96	320.83	390.54
Less: Excise Duty	0.24	0.28	0.05	0.88	1.13
01(a) Net Sales/Income from operations	50.37	14.14	15.91	319.95	389.41
(b) Other Income	3.30	0.61	5.61	7.09	10.28
Total Income	53.67	14.75	21.52	327.04	399.69
02) Expenditure					
(a) Increase / Decrease in stock in trade	14.39	-21.84	-0.84	-8.48	10.69
(b) Consumption of Raw materials	5.21	15.40	11.31	27.30	14.40
(c) Purchase of Traded goods	1.03	1.63	2.47	244.09	342.70
(d) Employee Cost	6.94	6.02	6.28	24.03	23.30
(e) Depreciation	1.11	1.97	1.88	7.02	7.88
(f) Other Expenditure	12.24	13.50	7.95	34.84	28.58
(g) Expenditure (a to f)	40.92	16.68	29.05	328.80	427.55
03) Profit from Operations before Other Income Interest & Exceptional items(1 - 2)	9.45	-2.54	-13.14	-8.85	-38.14
04) Other Income	3.30	0.61	5.61	7.09	10.28
05) Profit before Interest and Exceptional Items (3 + 4)	12.75	-1.93	-7.53	-1.76	-27.86
06) Interest	0.00	0.00	0.00	0.00	0.00
07) Profit after Interest but before Exceptional Items (5 - 6)	12.75	-1.93	-7.53	-1.76	-27.86
08) Exceptional Items	0.00	0.00	0.00	0.00	0.00
09) Profit(-) Loss from Ordinary Activities Before Taxation (7 + 8)	12.75	-1.93	-7.53	-1.76	-27.86
10) Tax Expense	0.00	0.00	0.00	0.00	0.00
11) Net Profit/(Loss) from Ordinary Activities after Taxation (9 - 8)	12.75	-1.93	-7.53	-1.76	-27.86
12) Extraordinary Item (net of tax expense Rs. _____)	0.00	0.00	0.00	0.00	0.00
13) Net Profit / Loss for the period (11-12)	12.75	-1.93	-7.53	-1.76	-27.86
14) Paid-up Equity Share Capital (Face Value of the share)	499.61 10.00	499.61 10.00	499.61 10.00	499.61 10.00	499.61 10.00
15) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00
16) Earning per Shares	0.2553	-0.0386	-0.1507	-0.0352	-0.56
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)					
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)					
17) Public Shareholding					
- No. of Shares	2397632	2400832	2415308	2397632	2415308
- Percentage of Shareholding	47.99	48.05	48.34	47.99	48.34
18) Promoters & Promoter Group Shareholding					
a) Pledged/Encumbered					
- No. of Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares(as% of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil
- Percentage of shares(as% of the total Share Capital of the Company)					
b) Non Encumbered					
- No. of Shares	2598468	2595268	2580792	2598468	2580792
- Percentage of Shares(as% of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%	100%
- Percentage of shares(as% of the total Share Capital of the Company)	52.01	51.95	51.66	52.01	51.66

* The above results were reviewed by the Audit Committee of the Board of Directors.

* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended March 31, 2012

* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 9th May, 2012.

* During this quarter the Company has operated in 2 segments.

* Investors complaints as at March 31, 2012:

Opening balance as on 01.01.2012 - Nil

Received during the quarter - 2

Closing balance as on: 31.03.2012 - Nil

Mumbai
May 9, 2012

By order of the Board
M.S. Raghavan Ayyangar
Managing Director

Emmessar Biotech & Nutrition Ltd

29, 4th Floor, Kamer Building, 38, Cawasji Patel Street, Fort, Mumbai - 400 001
Tel: 66356209/10/11; Fax: 91-22-66370190 Email: <contact@ebnl.co.in>

Quarterly Reporting of Segment wise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement:

(Rs. In Lakhs)

	Current Qtr ended 31st March 2012 (Unaudited)	Current Year ended 31st March 2012 (Unaudited)
1 Segment Revenue (Net sales/Income)		
a Healthcare	15.06	284.64
b Fine Chemicals	34.85	35.31
c Others	3.3	7.09
Total	53.21	327.04
Less: Inter segment revenue	0	0
Net sales / Income from Operations	53.21	327.04
2 Segment Results (Profit / Loss) before Tax and interest		
a Healthcare	8.06	25.62
b Fine Chemicals	20.24	21.29
c Others	3.3	7.09
Total	31.6	54
Less: Interest	0	0
Other Un Allocable Expenditure net off unallocable income	18.85	55.75
Total Profit before Tax	12.75	-1.75
3 Capital Employed (Segment assets - Segment liabilities)		
a Healthcare	22.41	22.41
b Fine Chemicals	1.59	1.59
c Others	0	0
Total	24	24

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

We operated only in 1 segment for the previous year.

The above results were taken on record at a meeting of the Board of Directors held on May 9, 2012.

Mumbai
May 9, 2012

By order of the Board
M.S. Raghavan Ayyangar
Managing Director

EMMESSAR BIOTECH & NUTRITION LTD		
Un Audited Statement of Assets & Liabilities as on 31st March 2012		
		(Rs. In Lakhs)
	12 months	12 months
Particulars	ended	ended
	31.03.2012	31.3.2011
	Unaudited	Audited
Shareholder's Fund		
(a) Capital	499.61	499.61
(b) Reserves & Surplus	6.39	6.39
Loan Funds	0.00	0.00
Total	506.00	506.00
Fixed Assets	189.99	196.47
Investments	0.47	0.44
Current Assets, Loans & Advances		
(a) Inventories	17.35	13.35
(b) Sundry Debtors	474.38	222.99
(c) Cash & Bank Balances	6.13	7.59
(d) Sundry Deposits	0.46	0.46
(e) Other Current Assets	4.29	3.39
(f) Loans & Advances	2.62	4.42
LESS: Current Liabilities & Provisions		
(a) Liabilities	471.71	224.88
(b) Provisions	9.52	8.01
Miscellaneous Expenditure	0.00	0
(Not written off or adjusted)		
Profit & Loss Account	291.54	289.78
Total	506.00	506.00